Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Living Cell Technologies ( (AU:1AI) ) just unveiled an update.
Algorae Pharmaceuticals has closed its non-renounceable pro-rata loyalty options entitlement offer, receiving applications for 199,013,513 options at $0.001 each and raising approximately $199,014 before costs, with the options expected to be issued on 22 December 2025. The remaining 138,737,943 options constitute a shortfall that will be placed at the company’s discretion under a separate shortfall offer within three months, with funds from both offers earmarked for offer costs and general working capital, modestly strengthening Algorae’s balance sheet and providing incremental support for its AI-driven drug discovery and commercialisation activities.
More about Living Cell Technologies
Algorae Pharmaceuticals is an ASX-listed, AI-enabled pharmaceutical company focused on drug-combination discovery and pharmaceutical commercialisation. Its proprietary AlgoraeOS platform uses machine learning and deep neural networks to identify synergistic drug combinations and optimise dosing for preclinical development, while its AlgoraeRx unit sources, licenses and supplies generic and specialty medicines in Australia and New Zealand through partnered manufacturers and established distribution channels.
YTD Price Performance: 50.0%
Average Trading Volume: 3,315,443
Technical Sentiment Signal: Buy
Current Market Cap: A$25.33M
Find detailed analytics on 1AI stock on TipRanks’ Stock Analysis page.